Seelos Therapeutics, Inc. (SEEL)

NASDAQ: SEEL · IEX Real-Time Price · USD
0.955
-0.021 (-2.14%)
Aug 16, 2022 11:32 AM EDT - Market open
-2.14%
Market Cap 101.85M
Revenue (ttm) n/a
Net Income (ttm) -73.35M
Shares Out 106.69M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 182,463
Open 0.967
Previous Close 0.976
Day's Range 0.944 - 0.970
52-Week Range 0.480 - 2.790
Beta 2.45
Analysts Buy
Price Target 6.29 (+558.9%)
Earnings Date Aug 8, 2022

About SEEL

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatm... [Read more...]

Industry Pharmaceuticals
Founded 2016
CEO Raj Mehra
Employees 15
Stock Exchange NASDAQ
Ticker Symbol SEEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SEEL stock is "Buy." The 12-month stock price forecast is 6.29, which is an increase of 558.91% from the latest price.

Price Target
$6.29
(558.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in ...

SLS-005 Study on the HEALEY ALS Platform is Expected to Complete Enrollment this Quarter; Top-Line Data Readout Expected Mid-2023 NEW YORK , July 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasd...

Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Al...

- A Single Dose of SLS-004 Produced 19% Downregulation of mRNA and ~40% Reduction of Alpha-Synuclein Compared to the Control Group - These Results Support Advancing SLS-004 into Additional Preclinical S...

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007

NEW YORK , May 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

NEW YORK , May 12, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference

NEW YORK , April 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorder...

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenix...

NEW YORK , April 11, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorder...

Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Governmen...

NEW YORK, March 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update

NEW YORK, March 7, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in A...

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

iX Biopharma will receive an initial US$9 million upfront payment Eligible for up to US$239 million in development and sales milestone payments Double digit royalties on future product sales of any lice...

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery ...

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control Disorder

The FDA has accepted Seelos Therapeutics Inc's (NASDAQ: SEEL) Investigation New Drug application to study SLS-005 (trehalose injection, 90.5 mg/mL) for spinocerebellar Ataxia (SCA).  The FDA has also gr...

Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designat...

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

Seelos Therapeutics to Participate in Two Investor Conferences

NEW YORK, Nov. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders a...

Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results

Part A results from the trial of Seelos Therapeutics Inc's (NASDAQ:SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in...

Is the Options Market Predicting a Spike in Seelos (SEEL) Stock?

Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.

Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial

The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass General Brigham Institutional Review Board to add SLS-005 (trehalose injection, 90.5 mg/ML for intrave...

Seelos Therapeutics to Participate in Two Investor Conferences in September

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors

NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...

Seelos Therapeutics Announces Senior Management Appointments

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...